Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Z-338. Zeria/Yamanouchi.

Anders Lehmann1

  • 1Integrative Pharmacology, Gastrointestinal Biology, AstraZeneca R&D Mölndal, Sweden. anders.lehmann@astrazeneca.com

Current Opinion in Investigational Drugs (London, England : 2000)
|August 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retrograde cricopharyngeus dysfunction (R-CPD), also known as inability to belch syndrome-a narrative review.

Translational gastroenterology and hepatology·2026
Same author

A Proof-of-Concept Study on the Effects of STA363 on Low Back Pain in Patients with Degenerative Disc Disease.

Spine·2025
Same author

[Retrograde cricopharyngeal dysfunction (inability to belch) - a »new« diagnosis that deserves attention].

Lakartidningen·2024
Same author

Translational Studies on Biologic Fusion of a Vertebral Segment as a Novel Treatment Modality for Low Back Pain.

Spine·2020
Same author

Weight Perturbation Alters Leptin Signal Transduction in a Region-Specific Manner throughout the Brain.

PloS one·2017
Same author

Intestinal SGLT1 in metabolic health and disease.

American journal of physiology. Gastrointestinal and liver physiology·2016

Zeria and Yamanouchi are developing Z-338, a novel prokinetic agent, for treating dyspepsia and gastric motility issues. This thiazole-4-carboxamide derivative is currently undergoing Phase II clinical trials.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Dyspepsia and gastric motility disorders represent significant unmet medical needs.
  • Current treatments offer limited efficacy for some patient populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of Z-338 as a potential therapeutic agent for dyspepsia.
  • To assess the prokinetic effects of Z-338 in patients with gastric motility disorders.

Main Methods:

  • Z-338, a thiazole-4-carboxamide derivative, is being developed.
  • The compound is currently in Phase II clinical trials.

Main Results:

  • Preliminary data on Z-338's prokinetic activities are being gathered.
  • The compound is being evaluated for its potential to improve gastric emptying and reduce dyspeptic symptoms.

Related Experiment Videos

Conclusions:

  • Z-338 shows promise as a novel treatment for functional gastrointestinal disorders.
  • Further clinical investigation is warranted to establish its therapeutic role.